Pharmaceutical News

RSS

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc.

24 Oct 2009

Human clinical trials of TissuGlu to commence in Germany

Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu® in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive being developed for its first intended use to adhere surgical tissues together in large flap surgeries.

24 Oct 2009

MPI Research to assist Kineta in autoimmune drug development program

MPI Research, a preclinical Contract Research Organization (CRO), announced that it will be collaborating with Kineta, Inc, a Seattle-based privately held biotechnology company specializing in clinical advancement of drugs that modulate and enhance the human immune system.

24 Oct 2009

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

The U.S. Food and Drug Administration announced today that, in response to a request from the U.S. Centers for Disease Control and Prevention, it has issued an emergency use authorization (EUA) for the investigational antiviral drug peramivir intravenous (IV) in certain adult and pediatric patients with confirmed or suspected 2009 H1N1 influenza infection who are admitted to a hospital.

24 Oct 2009

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

TransMolecular, Inc., a developer of innovative oncology drugs through targeted delivery technologies, today announced final results from its Phase 2 clinical study comparing the toxicity and overall survival of three versus six intracavitary injections of its anti-cancer compound 131I-TM601 in the treatment of recurrent malignant glioma.

24 Oct 2009

Media examines U.S., Mexico H1N1 vaccine campaigns, health effects of handwashing in Bolivia

The Washington Post examines H1N1 vaccine supplies across the U.S.: "With only a fraction of the tens of millions of doses of vaccine that authorities predicted would be available arriving in states, cities and towns, public health officials who spent months planning for a massive immunization program are instead scrambling to parcel out their limited supply of nasal sprays and shots," the newspaper writes.

24 Oct 2009

Nutri5, an effective natural product for the relief of menopausal symptoms

Earlier this year, the BBC reported that "HRT - Hormone Replacement Therapy - can shrink women's brains"1, after a study was published which showed that brain volume in women taking HRT was smaller in two key areas involved in thinking and memory.

23 Oct 2009

EFPIA launches a pilot project against counterfeit prescription medicines in Europe

This incidence of counterfeit prescription medicines in Europe's traditional supply chain is growing. This is why EFPIA (European Federation of Pharmaceutical Industries and Associations) has launched a pilot project that includes the testing of a coding and identification solution in Sweden.

23 Oct 2009

Vaccine Vial Monitors to monitor potential heat damage of H1N1 vaccines donated to WHO

Temptime Corporation announced today that it will donate its Vaccine Vial Monitors (VVMs) to the World Health Organization (WHO) to monitor potential heat damage of H1N1 vaccines to be distributed by WHO to developing countries most in need.

23 Oct 2009

Shire announces new pharmacokinetic data of ADHD medication

Shire plc, the global specialty biopharmaceutical company, announced new data about the pharmacokinetics of its Attention-Deficit/Hyperactivity Disorder (ADHD) medication, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, which showed that Vyvanse provided similar concentrations of its active medication in the blood when administered either intranasally or when administered orally.

23 Oct 2009

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Boehringer Ingelheim announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Evaluation Agency (EMEA) has issued a positive opinion for the approval of MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity.

23 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. today announced the companies have begun enrolling patients in an international Phase 3 trial to evaluate Nexavar® (sorafenib) tablets for the treatment of patients with radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer.

23 Oct 2009

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of rheumatoid arthritis in the United States through 2011, but the more established branded drugs such as, Centocor Ortho Biotech's Remicade, Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face competition from newer entrants.

23 Oct 2009

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China, today announced that it has received a Certificate of Approval from the Secretaria de Salud to distribute PANFLU.1, its H1N1 pandemic influenza (swine flu) vaccine, in Mexico. The certificate is valid through October 13, 2014.

23 Oct 2009

Antidepressant prescriptions are on the rise

A dramatic rise in antidepressant prescriptions issued by GPs has been caused by a year on year increase in the number of people taking antidepressant drugs on a long-term basis, according to researchers from the University of Southampton.

23 Oct 2009

Study: General anesthesia can cause brain injury in immature rats

Studies by researchers at Wake Forest University School of Medicine have shown that blocking the NMDA receptor in immature rats leads to profound, rapid brain injury and disruption of auditory function as the animals mature.

23 Oct 2009

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Biotech company Pharming Group NV announced today publication of a preclinical study showing the benefit of using recombinant human C1 inhibitor (rhC1INH) in ischemic brain injury.

23 Oct 2009

Relationship between cannabis and schizophrenia is controversial

Last year the UK government reclassified cannabis from a class C to a class B drug, partly out of concerns that cannabis, especially the more potent varieties, may increase the risk of schizophrenia in young people. But the evidence for the relationship between cannabis and schizophrenia or psychosis remains controversial.

23 Oct 2009

MedImmune announces interim data from its live attenuated influenza vaccine studies

MedImmune announced today that interim data from human studies of its nasal spray vaccine for the 2009 novel Influenza A (H1N1) virus demonstrate a similar clinical profile in children and adults 2 to 49 years of age as previously studied seasonal formulations of the vaccine.

23 Oct 2009

Pharmaceutical News

Potentia Pharmaceuticals and Alcon Research sign license and purchase option agreements

Human clinical trials of TissuGlu to commence in Germany

MPI Research to assist Kineta in autoimmune drug development program

FDA issues emergency use authorization for intravenous antiviral drug peramivir in H1N1 patients

TransMolecular announces final results from its Phase 2 clinical study of 131I-TM601

Media examines U.S., Mexico H1N1 vaccine campaigns, health effects of handwashing in Bolivia

Nutri5, an effective natural product for the relief of menopausal symptoms

EFPIA launches a pilot project against counterfeit prescription medicines in Europe

Vaccine Vial Monitors to monitor potential heat damage of H1N1 vaccines donated to WHO

Shire announces new pharmacokinetic data of ADHD medication

Boehringer Ingelheim receives European CHMP positive opinion for MICARDIS

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals start Phase 3 trial to evaluate Nexavar tablets

Decision Resources predicts TNF-alpha inhibitors to dominate rheumatoid arthritis treatment

Sinovac Biotech to distribute PANFLU.1 vaccine in Mexico

Antidepressant prescriptions are on the rise

Study: General anesthesia can cause brain injury in immature rats

Study reveals benefits of recombinant human C1 inhibitor in treating ischemic brain injury

Relationship between cannabis and schizophrenia is controversial

MedImmune announces interim data from its live attenuated influenza vaccine studies

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News